Find Articles in:
All
Business
Reference
Technology
News
Lifestyle

Intron-A/Aldara combination therapy for BCC

Journal of Drugs in Dermatology, Feb, 2008

Sponsored by: The University of Texas Health Science Center, Houston. The purpose of this study is to see if BCC excluding the scalp and face can be treated successfully with a combination therapy of Intron[R]-A and Aldara[R].

Condition             Intervention            Phase

Basal Cell Carcinoma  Biological: Imiquimod   Phase IV
  Excluding Scalp       and Interferon alpha
  and Face

Study ID Numbers: HSC-MS-06-0478, OSP-24412

ClinicalTrials.gov Identifier: NCT00581425

COPYRIGHT 2008 Journal of Drugs in Dermatology, Inc.
COPYRIGHT 2008 Gale, Cengage Learning
 

BNET TalkbackShare your ideas and expertise on this topic

The following tags are supported in BNET comments:
<b></b> <i></i> <u></u> <pre></pre>

Leave a Reply

  1. You are currently a guest | Login?
advertisement
Go
advertisement
  • Click Here
  • Click Here
advertisement

Content provided in partnership with Thompson Gale